International Society for Hepatic Encephalopathy and Nitrogen Metabolism

Abstract Submission has been closed.

Scientific Program

 

ISHEN 2017

 

Day 1 [Pathogenesis]; March 9, 2017

 

Day 1: Pathogenesis
8:00-8:15
Welcome notes
8:15-10:00
Hepatic Encephalopathy: What are the main challenges?
Learning Objective:
To review current knowledge and future challenges
Chairs:
Radha K. Dhiman and Sara Montagnese

 

TimeTitle of the TalkDurationSpeakerCountry
8:15-8:40 Pathogenesis 25 min Christopher Rose  Canada
8:40-9:05 Diagnosis and classification 25 min Piero Amodio  Italy
9:05-9:30 Treatment 25 min Rajiv Jalan  U.K
9:30-10:00 Combined Discussion 30 min    

 

10:00-10:30
Refreshment Break
10:30-12:20
SESSION 1:Pathogenesis- 1 (BRAIN EDEMA)
Learning Objective:
To understand the role of brain edema in HE, what causes brain edema, intracranial hypertension and the role of the blood brain barrier
Chairs:
Peter Ott and Sunil Taneja
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
10:30-10:50 Neurochemistry of hepatic encephalopathy 20 min Alexander Gourine  U.K
10:50-11:10 Blood brain barrier in HE 20 min Nicolaas Weiss  France
11:10-11:30 Cause or effect of HE 20 min Veronika Rackayova Switzerland
11:30-11:50 Combined Discussion 20 min    
11:50-12:05 Abstr #1: Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease 10+5 min Anna Hadjihambi  France
12:05-12:20 Abstr#2: Ammonia mediated brain-oedema and immune dysfunction is mediated by toll-like receptor (TLR) 9 10+5 min Godhev K Manakkat Vijay  U.K
12:20-13:20
Lunch
13:20-15:10
SESSION 2:Pathogenesis- 2
Learning Objective:
It will comprise a series of talks by established ISHEN members to establish the basic understanding of the key science areas related to pathogenesis of hepatic encephalopathy.
Chairs:
Dieter Haussinger and Shiv Sarin.
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
13:20-13:40 Ammonia and neurotoxicity 20 min  A.R. Jayakumar  U.S.A
13:40-14:00 Neuronal cell loss in HE 20 min Roger Butterworth  Canada
14:00-14:20 Inflammation 20 min Mark Swain  Canada
14:20-14:40 Combined Discussion 20 min    
14:40-14:55 Abstr# 3. Glutamine synthetase in endothelial cells of the blood-brain barrier: Less but not insignificant? 10+5 min Mariana Macedo Oliveira   Canada
14:55-15:10 Abstr# 4. Ammonia affects iron homeostasis in cultured rat astrocytes and in human cerebral cortex in hepatic encephalopathy 10+5 min Ayse Karababa   Germany

15:10-15:40

Tea break

15:40-17:45

SESSION 3:Pathogenesis – 3
Learning Objective:
It will comprise a series of talks by established ISHEN members to establish the basic understanding of the key science areas related to pathogenesis of hepatic encephalopathy.
Chairs:
AR Jayakumar and Nathan Davies

Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
15:40-16:55 Cerebral blood flow and brain bioenergetics 15 min Peter Bjerring  Denmark
16:55-16:10 Role of Bile acids 15 min Sharon De Morrow  U.S.A
16:10-16:25 Ammonia and senescence 15 min Boris Gorg  Germany
16:25-16:40 Combined Discussion 15 min    
16:40-16:55 Abstr# 5. Role of endothelial NMDA receptors in the pathogenesis of hepatic encephalopathy 10+5 min Marta Skowronska  U.S.A
16:55-17:10 Abstr#6. Neuronal dysfunction in chronic hepatic encephalopathy: Role of astrocytic matricellular proteins 10+5 min A.R. Jayakumar  U.S.A

 

17:10-17:45
Andy Blei Lecture
 
Chairs:Radha K. Dhiman and Sara Montagnese
 
Speaker:Dieter Häussinger
 
Title:Pathomechanisms of Hepatic Encephalopathy
18:00-19:30
Poster sessions with wine and Indian traditional snacks
19:30
Dinner
 

 

 

 

 

 

ISHEN 2017

Day 2 [Diagnosis] March 10, 2017

 

08:00-10:00
SESSION 4: WORKSHOP 1 (CLINICAL): MINIMAL/COVERT HEPATIC ENCEPHALOPATHY
Learning Objective:
The diagnosis and manage of minimal/covert HE is one of the most contentious issues in the area of hepatic encephalopathy. Following issues will be discussed
Chairs:
Karin Weissenborn and Shalimar
Speakers:

 

TimeTitle of the TalkDurationSpeakerCountry
8:00-8:10 Who is normal (Normal mental state) 10 min Sara Montagnese  Italy
8:10-8:20 Is it rational to combine MHE and Grade 1 10 min Jasmohan Bajaj  U.S.A
8:20-8:30 Who should be tested? 10 min Marsha Morgan  U.K
8:30-8:40 MHE testing in real world scenario 10 min Mette Lauridsen  Denmark
8:40-8:50 Prospective large scale MHE validation strategies 10 min Andres Duarte-Rojo  U.S.A
8:50-9:00 MHE testing in an ideal situation 10 min Manuel Romero-Gomez  Spain
9:00-9:30 Panel Discussion 30 min    
9:30-9:45 Abstr# 7. The brain-muscle axis in minimal hepatic encephalopathy (MHE): a placebo-controlled, longitudinal double-blind trial with Lornithine L-aspartate (LOLA) - Preliminary results 10+5 min Yasmin Pasha  U.K
9:45-10:00 Abstr# 8. Comparative effectiveness of different pharmacological interventions for the treatment of minimal hepatic encephalopathy: a systematic review with network meta-analysis 10+5 min Kiran K Thumburu  India

 

08:00-10:00
SESSION 5: WORKSHOP 2 (BASIC): ANIMAL MODELS
Learning Objective:
To review the animal models used to study hepatic encephalopathy
Chairs:
Roger Butterworth and Rakesh Vasishta
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
8:00-8:17 Acute liver failure (Type A hepatic encephalopathy) 17 min Scott Nyberg  U.S.A
8:17-8:34 Type B hepatic encephalopathy 17 min Marc Oria  U.S.A
8:34-8:51 Chronic liver disease(Type C hepatic encephalopathy) 17 min Christopher Rose  Canada
8:51-09:08 Acute on chronic liver failure 17 min Natalia Arias  U.K
9:08-9:30 Panel Discussion 22 min    
9:30-9:45 Abstr#9. The neurosteroid DHEAS reverses the concomitant gliopathy and dopaminergic dysfunction in mild hepatic encephalopathy : A focus on neuro-glial plasticities 10+5 min Omar EL Hiba  Morocco
9:45-10:00 Abstr#10. Probiotic treatment improves outcome of chronic hepatic encephalopathy in BDL rats, an in vivo longitudinal 1h MRS study 10+5 min Veronika Rackayova  Switzerland

 

10:00-10:30
Refreshment Break
10:30-12:30
SESSION 6:HEPATIC ENCEPHALOPATHY IN SPECIAL SITUATIONS
Learning Objective:
To review the current classification of HE and also to find out whether further improvement/change is required?
Chairs:
Fin Larsen and Marsha Morgan
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
10:30-10:45 Epidemiology, types and diagnosis 15 min Lise-lotte Gluud
 Denmark
10:45-11:00 Alcohol: Withdrawal / Intoxication / Wernicke's 15 min Sandeep Grover  India
11:00-11:15 Hepatic encephalopathy related to ACLF: Is it different? 15 min Rajiv Jalan  U.K
11:15-11:30 Pre/post transplant HE management 15 min Simone Rasko Strasser  Australia
11:30-11:45 Combined discussion 15 min    
11:45-12:00 Abstr# 11. Changes in brain integrity underlying cognitive and functional recovery following liver transplantation plateaus after six months 10+5 min Vishwadeep Ahluwlia  U.S.A
12:00-12:15 Abstr# 12. Neurological impairment in cirrhotic patients admitted to ICU: Hepatic versus drug-induced encephalopathy 10+5 min Maxime Mallette  France
12:15-13:00
Lunch
13:30-15:00
SESSION 7: ACUTE LIVER FAILURE
Learning Objective:
To review the pathogenesis and late outcome of ALF
Chairs:
Scott Nyberg and Yogesh Chawla
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
13:00-13:20 Neurological Monitoring in ALF 20 min Banwari Agarwal  U.K
13:20-13:40 Role of Ammonia, Inflammation and other factors in pathogenesis of brain edema 20 min Subrat Acharya  India
13:40-14:00 Neurological recovery after recovery from acute liver failure (both spontaneous or after liver transplantation):Is it complete? 20 min Anil C Anand  India
14:00-14:15 Combined Discussion 15 min    
14:15-14:30 Abstr#13. TGFΒ1 suppresses neuronal IGF1 via a LET-7F-dependent mechanism during azoxymethane-induced hepatic encephalopathy in mice 10+5 min Matthew McMillin  U.S.A
14:30:14:45 Abstr# 14. Increased expression of GLUT 1 in patients with acute liver failure 10+5 min Madhu Chopra  India
14:45-16:15
SESSION-8: MINIMAL HEPATIC ENCEPHALOPATHY: NEWER METHODS AND APPROACHES
Learning Objective:
Challenges in making the diagnosis of minimal HE
Chairs:
Gitte Dam and Subrat Acharya
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
14:45-15:00 Is 1 test better than 2? 15 min Piero Amodio  Italy
15:00-15:15 Non-specialized methods to screen MHE 15 min Mette Lauridsen  Denmark
15:15:15:30 Critical flicker frequency 15 min Gerald Kircheis  Germany
15:30-15:45 Impact of co-morbid conditions (Dementia, diabetes, etc) 15 min Karin Weissenborn  Germany
15:45-16:00 Abstr# 15. The continuous reaction times test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention 10+5 min Mette Munk Lauridsen  Denmark
16:00-16:15 Abstr# 16. Encephalapp and critical flicker frequency are associated with accidental falls in liver cirrhosis. 10+5 min Carmen Sendra  Spain
16:15-16:45
Tea break
16:45-18:00
SESSION-9: NEW TECHNOLOGIES – NEW INSIGHTS
Learning Objective:
This session will discuss the latest methodologies and techniques that can be used to examine HE and its related conditions. The focus should not necessarily be on the techniques themselves, but rather on the types of information that can be derived from them and how this may influence future treatment.
Chairs:
Boris Gorg and Simon Taylor Robinson
Speakers

 

TimeTitle of the TalkDiscussionSpeakerCountry
16:45-17:05 Genomics, proteomics and metabolomics 20 min Mark McPhail  U.K
17:05-17:25 Microbiome assessment 20 min Vishal Patel  U.K
17:25-17:45 Newer brain imaging techniques 20 min Rakesh Gupta  India
17:45-18:00 Abstr # 17. Derivation of decision algorithms for the diagnosis of hepatic encephalopathy in patients with cirrhosis 10+5 min Harry Zacharias  U.K
18:00-18:15 Abstr# 18. Drugs interactions and metabolomic profile during liposome-supported peritoneal dialysis (LSPD) in the treatment of severe hyperammonemia 10+5 min Giovanna Giacalone  Switzerland
18:15
Football Match or Tug of War
20:00
Dinner

 

ISHEN 2017

 

Day 3 [Treatment] March 11, 2017

 

08:00-10:00
SESSION 10: WORKSHOP 3 (CLINICAL): THE GUT, LIVER AND BRAIN AXIS
Learning Objective:
This session will consider the relationship between the three organ systems; the known ammonia trafficking that occurs between them; and the role of gut glutaminase. Importantly, the session will explore the role of dysbiosis, translocation, priming of the brain and targeting these processes as potential current and future therapeutic targets.
Chairs:
Rajiv Jalan and Manuel Romero-Gomez
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
8:00-8:20 Gut microbiota in health + methods of detection 20 min Rakesh Aggarwal  India
8:20-8:40 Alterations in gut microbiota in cirrhosis of liver and hepatic encephalopathy 20 min Jasmohan Bajaj  U.S.A
8:40-9:00 Gut-liver axis and alcoholic liver disease 20 min Gyongyi Szabo  U.S.A
9:00-9:20 Panel discussion 20 min    
9:20-9:35 Abstr # 19. Disturbances in the microcirculation on the surface of rat brain induced ammonium chloride is associated with increased periarteriolar adenosine concentration 10+5 min Peter Nissen Bjerring  Denmark
9:35-9:50 Abstr # 20. Skeletal muscle abnormalities increase the risk of overt hepatic encephalopathy and hyperammonemia in patients with cirrhosis 10+5 min Rahima A. Bhanji  Canada

 

08:00-10:00
SESSION 11: WORKSHOP 4 (BASIC): AMMONIA: MORE THAN JUST A NEUROTOXIN
Learning Objective:
This workshop will examine and discuss the evidence and mechanisms of toxic effect of ammonia other than neurotoxicity.
Chairs:
Christopher Rose and Raj Mookerjee
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
8:00-8:20 Liver, Kidney, Lung……… 20 min Balasubramaniyan Vairappan  India
8:20-8:40 Immune cells 20 min Vishal Patel  U.K 
8:40-9:00 Implication for fatty liver progression 20 min Karen Louise Thomsen  Denmark
9:00-9:20 Panel discussion 20 min    
9:20-9:35 Abstr # 21. Effect of resveratrol on tight junction proteins and hyperammonemia in cirrhosis 10+5 min Balasubramaniyan Vairappan  India
9:35-9:50 Abstr # 22. Taurine transporter deficiency induces hyperammonemia, oxidative stress and senescence in mouse liver 10+5 min Niloufar Monhasery  Germany
9:50-10:20
Refreshment Break
10:20-11:15
SESSION 12: DESIGN OF THERAPEUTIC CLINICAL TRIALS IN HE
Learning Objective:
This section will elaborate on the selection of patients, standards of care and end-points for assessing the treatment.
Chairs:
Piero Amodio and Ajay Duseja
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
10:20-10:40 What are the clinical end points for HE/MHE clinical trials? 20 min Lise-lotte Gluud  Denmark
10:40-11:00 How to design a multicenter clinical trial in HE? 20 min Oliviero Riggio  Italy
11:00-11:15 Combined discussion 15 min    
11:15-12:15
SESSION 13: TREATMENT: SPECIAL SITUATIONS
Learning Objective:
This section will elaborate on the treatment of minimal HE and ACLF and on the prevention of HE.
Chairs:
Ramesh Roop Rai and Mark Swain
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
11:15-11:35 Minimal hepatic encephalopathy 15+5 min Radha K. Dhiman  India
11:35-11:55 Primary and secondary prophylaxis 15+5 min Barjesh Sharma  India
11:55-12:15 Acute on chronic liver failure 15+5 min  Rajiv Jalan  U.K
12:15-13:15
Lunch
13:15-15:15
SESSION 14: TREATMENT: PHARMACOLOGICAL
Learning Objective:
To review the pharmacological treatment of HE
Chairs:
Barjesh Sharma and OlivieroRiggio
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
13:15-13:28 Lactulose 13 min Vivek A Saraswat  India
13:28-13:41 BCAA 13 min Gitte Dam  Denmark
13:41-14:54 Probiotics 13 min Radha K Dhiman  India
14:54-14:07 L-ornithine L-aspartate 13 min Roger Butterworth  Canada
14:07-14:20 Ornithine-Phenylacetate 13 min Nathan Davies  U.K
14:20-14:45 Combined Discussion 25 min    
14:45-15:00 Abstr# 23. Oral ornithine phenylacetate attenuates muscle mass loss and prevents hepatic encephalopathy in BDL rats 10+5 min Marc Andre Clement  Canada
15:00-15:15 Abstr # 24. Goal directed ammonia lowering therapy in acute on chronic liver failure (ACLF) with hepatic encephalopathy (HE): A randomized trial (clinicaltrials.gov identifier: NCT02321371) 10+5 min Tanmay S Vyas  India
15:15-15:45
Tea break
15:45-18:00
SESSION 15: TREATMENTS 2: NONPHARMACOLOGICAL
Learning Objective:
To review the non-pharmacological treatment of HE and liver failure
Chairs:
Shiv K. Sarin, Sandeep Sindhu and Jasmohan Bajaj
Speakers

 

TimeTitle of the TalkDurationSpeakerCountry
15:45-16:05 Liver Regeneration and Role of Niche and Bone Marrow: New insights 20 min Shiv K Sarin  India
16:05-16:20 Exercise-What we have learnt from animal models 15 min Chantal Bémeur  Canada
16:20-16:35 Exercise-Clinical experience 15 min Puneeta Tandon  Canada
16:35-16:50 Nutrition 15 min Manuela Merli  Italy
16:50-17:05 High volume plasma exchange / Albumin dialysis 15 min Fin Larsen  Denmark
17:05-17:20 Peritoneal dialysis 15 min Agostoni Valentina  
17:20-17:40 Combined Discussion 20 min    
17:40-17:55 ISHEN Fellowship Paper Award: Effects of anaerobic exercise in muscle strength and muscle mass optimization in bile duct ligated rats 10+5 min Luise Aamann  Denmark
17:55-18:10 Abstr # 25 Cognitive function following hepatitis C eradication in patients treated with direct antiviral agents: Results from a population-based study 10+5 min Luis Ibañez-Samaniego  Spain
18:10-18:25 Abstr # 26. Results of portosystemic shunt embolization in selected patients with cirrhosis and recurrent hepatic encephalopathy 10+5 min  Narendra S Choudhary   India
18:30
Group photograph
19:00
Gala Dinner and Prizes
Day 4:                                                      
Departures in the forenoon